Gilead Q3 2023: EPS beats on lower tax; raises full-year product sales guidance

GILEAD SCIENCES, INC.

2023-Q3 EPS reported $3.37 revenue$20,002,000,000

Total revenue $7.1B flat YoY; product sales ex-Veklury up 5% to $6.4B.
GAAP diluted EPS $1.73 vs $1.42 YoY; non-GAAP diluted EPS $2.29 vs $1.90.
Biktarvy sales grew 12% to $3.1B; Oncology sales up 33% to $769M.
Full-year product sales guidance raised to $26.7-26.9B; non-GAAP EPS raised to $6.65-6.85.
Veklury sales fell 31% to $636M; R&D expenses rose to $1.5B on clinical activity and magrolimab discontinuations.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GILEAD SCIENCES, INC. reported the third quarter of 2023 results: revenue $7.1 billion, EPS $1.73.

Period: the third quarter of 2023
Revenue: $7.1 billion
EPS: $1.73
Result: reported results

Exact text from the filing

Total third quarter 2023 revenue of $7.1 billion was flat compared to the same period in 2022, primarily driven by increased sales in Oncology and HIV, offset by lower Veklury

View on SEC.gov

Browse all earnings releases →

GILEAD SCIENCES, INC. filing history →

Source: SEC EDGAR

accession 0000882095-23-000029

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.